EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity

Martina Gambron iD, Elena Peruzzi, Samantha Perfler, Marcella Montico, Riccardo Cecchin, Elena De Mattia iD, Michele Spina, Camilla Lisanti, Serena Corsetti, Luisa Foltran, Fabio Puglisi, Rossana Roncato und 1 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Martina Gambron und 12 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Irinotecan, Dihydrouracil Dehydrogenase (NADP), Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health (Ricerca Corrente), Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DPYD and UGT1A1 variants significantly affect fluoropyrimidines and irinotecan safety. While genotype‐driven dosing reduces severe toxicity, the impact of individual variants remains incompletely investigated. This retrospective cohort study includes 178 cancer patients with a matched actionable DPYD and/or UGT1A1 genotypes, defined by the presence of guideline‐recommended variants ( DPYD : rs3918290, DPYD *2A, c.1905+1G>A; rs55886062, DPYD *13, c.1679T>G; rs67376798, c.2846A>T; rs56038477, c.1236G>A (HapB3); UGT1A1 : rs8175347, UGT1A1 *28/*37 and rs4148323, UGT1A1 *6, c.211G>A), and treated with fluoropyrimidines and/or irinotecan. Patients were classified into standard‐of‐care (posttreatment genotyping; n = 97) or genotype‐driven group (pretreatment genotyping with DPWG‐driven dosing; n = 81). Clinically relevant toxicity and relative dose intensity (RDI), a proxy for drug exposure, were evaluated by genotype. Genotype‐driven dosing significantly reduced overall clinically relevant toxicity (16.0% vs. 43.3%; p < 0.001). Among DPYD c.1905+1G>A heterozygous carriers, clinically relevant toxicities occurred only within standard‐of‐care (61.5% vs. 0%, p = 0.007), with lower RDI despite full starting dose (41% [IQR 13–62] vs. 48% [IQR 46–50], p = 0.425). In DPYD c.2846A>T heterozygous carriers, standard‐of‐care had slightly higher RDI (63% [IQR 54–80] vs. 50% [IQR 43–50], p = 0.007) but doubled toxicity rate (27% vs. 67%, p = 0.092). Conversely, DPYD c.1236G>A (HapB3) heterozygous carriers experienced similarly low toxicity rates (23.7 vs. 13.2, p = 0.375), but genotype‐driven dosing markedly reduced RDI (50% [IQR 43–55] vs. 82% [IQR 63–92], p < 0.001). In UGT1A1 *28 homozygous carriers, genotype‐driven dosing reduced toxicity (21.1% vs. 45.7%, p = 0.086) while preserving comparable RDI (58% [IQR 50–69] vs. 61% [IQR 41–76], p = 0.906). These findings suggest uniform genotype‐based strategies may not fully capture variant‐specific effects, particularly for DPYD c.1236G>A (HapB3), supporting more flexible dosing approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucuronosyltransferaseIrinotecanDihydrouracil Dehydrogenase (NADP)Antineoplastic Combined Chemotherapy ProtocolsNeoplasmsHumansUGT1A1 EnzymeFemaleGenotypeRetrospective StudiesMiddle AgedAgedMaleAdultFluorouracil

Stichwörter der Autor:innen

DPYDUGT1A1dose intensitypharmacogenetic testingprecision dosing

Substanzen

GlucuronosyltransferaseIrinotecanUGT1A1 EnzymeDihydrouracil Dehydrogenase (NADP)Fluorouracil

Autor:innen und Institutionen

  • Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Scientific Directorate, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Division of Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Department of Medicine (DMED), University of Udine, Udine, Italy.

ORCID-Profile: Martina Gambron, Elena De Mattia

Förderung

  • Italian Ministry of Health (Ricerca Corrente)
  • Ministero della Salute

Zitieren

APA

Gambron, M., Peruzzi, E., Perfler, S., Montico, M., Cecchin, R., De Mattia, E., Spina, M., Lisanti, C., Corsetti, S., Foltran, L., Puglisi, F., Roncato, R., & Cecchin, E. (2026). DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity. International Journal of Cancer. https://doi.org/10.1002/ijc.70580

Vancouver

Gambron M, Peruzzi E, Perfler S, Montico M, Cecchin R, De Mattia E, et al. DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity. International Journal of Cancer. 2026. doi:10.1002/ijc.70580

BibTeX
@article{Gambron2026,
  author = {Gambron, Martina and Peruzzi, Elena and Perfler, Samantha and Montico, Marcella and Cecchin, Riccardo and De Mattia, Elena and Spina, Michele and Lisanti, Camilla and Corsetti, Serena and Foltran, Luisa and Puglisi, Fabio and Roncato, Rossana and Cecchin, Erika},
  title = {DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70580}
}
Kostenlos starten →